FINHUB Insights

BDX · Q1 FY26 · Oct 1 – Dec 31, 2025

Becton Dickinson Q1 FY26: where the revenue came from and where it went

Becton Dickinson Q1 FY26: revenue $5.3B (+2% year over year). Net profit $0.4B. Largest cohort Medical Essentials $1.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 9, 2026 10-Q
Sankey diagram of Becton Dickinson's income statement for Q1 FY26: revenue of $5.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.3B +2% year over year
Gross profit$2.4B 46% margin
Operating profit$0.6B 11% margin
Net profit$0.4B 7% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 5.3 100% +2%
Medical Essentials 1.6 30% +1%
Interventional 1.3 25% +6%
Connected Care 1.1 21% +5%
Life Sciences 0.8 15% −8%
Bio Pharma Systems 0.4 8% +3%
Cost of revenue−2.853%
Gross profit2.446% margin+3pp
Research & development−0.36%−1pp
SG&A−1.427%+1pp
Other−0.23%+0pp
Operating profit0.611% margin+2pp
Interest & other costs−0.2
Net profit0.47%+1pp
Filing on EDGAR More quarters of BDX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters